Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 26 P318

ECE2011 Poster Presentations Obesity (47 abstracts)

Serum adiponectin levels in patients with type 1 gaucher disease

S Petakov 1, , N Suvajdzic 1, , S Ognjanovic 2 , T Isailovic 2 , D Macut 1, , M Djurovic 1, , I Bozic 2 & S Damjanovic 1,


1Medical school of Belgrade university, Belgrade, Serbia; 2Clinic of Endocrinology, Belgrade, Serbia; 3Clinic for Hematology, Belgrade, Serbia.


Gaucher disease (GD) is autosomal recessive lysosomal storage disorder caused by the deficiency of glucocerebrosidase with consequent massive acumulation of lipid-laden macrophages in various tissues. Estimated life expectancy is about 9 years shorter than for the reference population. Mortality due to macrovascular diseases is higher, and probably associated with metabolic abnormalities found in GD type 1 patients, including decreases in serum adiponectin levels. Because adiponectin is thought to have antiatherogenic and anti-inflammatory properties, we studied its serum concentration in a cohort of 15 patients with type 1 GD (9 females and 6 males, mean age 44.2±3.4 years) and 20 age and BMI-matched healthy control subjects (13 females and 7 males, mean age 40.9±3.2 years). We found no difference in serum adiponectin level in patients with GD type 1 as compared with healthy subjects (mean±S.E.M., 69.9±6.9 vs 73.0±10.8 ng/ml respectively). There was no difference in serum adiponectin levels between untreated and treated patients with type 1 GD. There was no correlation between body mass index and adiponectin levels even in group of GD patients on enzyme replacement treatment (n=10). In conclusion our results does not confim previous results concerning the existance of hypoadiponectinemia in untreated and treated patients with GD type 1. Probably adiponectin has no role in decreased life expectancy due to macrovascular morbidity in these patients.

Article tools

My recent searches

No recent searches.